首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >QBD-BASED DEVELOPMENT AND EVALUATION OF ENTERIC COATED MUCOADHESIVE MICROCAPSULES OF AMOXICILLIN TRIHYDRATE AS A NOVEL CHRONOTHERAPEUTIC APPROACH FOR TREATMENT OF BACTERIAL INFECTIONS
【24h】

QBD-BASED DEVELOPMENT AND EVALUATION OF ENTERIC COATED MUCOADHESIVE MICROCAPSULES OF AMOXICILLIN TRIHYDRATE AS A NOVEL CHRONOTHERAPEUTIC APPROACH FOR TREATMENT OF BACTERIAL INFECTIONS

机译:基于QBD的三水硫酸阿莫西林肠溶衣微囊微胶囊的开发和评价作为治疗细菌感染的新的慢性治疗方法

获取原文
获取外文期刊封面目录资料

摘要

Objective: The present work entails design and characterization of enteric coated mucoadhesive microcapsules loaded with amoxicillin trihydrate as a novel chronotherapeutic approaches for the treatment and management of bacterial infection. Methods: The microcapsules were prepared by solvent evaporation technique using ethyl cellulose (EC) and hydroxypropyl methylcellulose (HPMC) as rate-controlling and mucoadhesive polymers, followed by a triple coating with Eudragit L100 as enteric coating polymer. Box-Behnken statistical design (BBD) was applied for optimization of formulations containing EC, HPMCK100M and Eudragit L100 as factors for selected responses like entrapment efficiency, mucoadhesive property and drug release in 24 h. The optimized microcapsules were also characterized for particle size, drug content, swelling index, mucoadhesive strength, and in vivo antiulcer activity. Results: The optimized microcapsules exhibited good entrapment efficiency, particle size and mucoadhesive property. FT-IR studies revealed that there was no drug-polymer interaction. SEM studies revealed that microcapsules were non-aggregated, spherical in shape and smooth appearance. In vitro drug release data from microcapsules was fitted to different kinetic models to explain release profiles. The correlation coefficient (r 2 ) value indicated that drug release followed Higuchi model. Analysis of variance (ANOVA) showed significant difference in the release of drug from all the prepared formulations at P 0.05 level. Accelerated stability study of optimized formulation (F4) upto 6 month showed there was no change in drug content and release characteristics during storage.
机译:目的:目前的工作需要设计和表征载有三水阿莫西林的肠溶性粘膜粘附微胶囊,作为治疗和管理细菌感染的新型计时疗法。方法:通过溶剂蒸发技术,以乙基纤维素(EC)和羟丙基甲基纤维素(HPMC)作为控制速率和粘膜粘附性聚合物,然后以Eudragit L100作为肠溶衣聚合物进行三层包衣,制备微囊。 Box-Behnken统计设计(BBD)用于优化包含EC,HPMCK100M和Eudragit L100的制剂,这些制剂是诸如24小时内包封率,粘膜粘附性和药物释放等选定响应的因素。还对优化的微胶囊的粒径,药物含量,溶胀指数,粘膜粘附强度和体内抗溃疡活性进行了表征。结果:优化的微胶囊具有良好的包封率,粒径和粘膜粘附性能。 FT-IR研究表明没有药物-聚合物相互作用。 SEM研究表明,微胶囊是非聚集的,球形的和光滑的外观。来自微囊的体外药物释放数据适合不同的动力学模型以解释释放曲线。相关系数(r 2)值表明药物释放遵循Higuchi模型。方差分析(ANOVA)显示,所有制备的制剂在P <0.05水平上药物释放的显着差异。优化配方(F4)长达6个月的加速稳定性研究表明,储存期间药物含量和释放特性没有变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号